• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Dabigatran linked to fewer major bleeding events than warfarin in ablation: The RE-CIRCUIT trial

byAndrew Cheung, MD MBAandMatthew Growdon
April 28, 2017
in Cardiology, Chronic Disease, Public Health, Surgery
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. The incidence of major bleeding events up to 8 weeks after catheter-directed atrial fibrillation ablation was significantly lower in those receiving continuous therapy with dabigatran compared to those receiving INR-directed warfarin.

2. Both groups experienced similar incidence of minor bleeding events and thromboembolic events.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Catheter-directed ablation therapy of paroxysmal and persistent atrial fibrillation is a relatively common procedure, with the most feared potential complication being stroke. Prior research has linked uninterrupted therapy with warfarin during the time of ablation with a lower risk of periprocedural bleeding and stroke compared to stopping warfarin and bridging with low-molecular-weight heparin. However, there are gaps in our understanding regarding the relative risks and benefits of uninterrupted non-vitamin K antagonist oral anticoagulant therapy around the time of ablation.

The RE-CIRCUIT trial involved 635 patients who underwent catheter ablation for atrial fibrillation, randomizing them to receive 4 to 8 weeks of uninterrupted anticoagulation with either warfarin or dabigatran. The incidence of major bleeding events up to 8 weeks after ablation was significantly lower in the dabigatran group compared to the warfarin group, and both groups experienced similar incidence of minor bleeding events and thromboembolic events. These findings advance the possibility that continuous therapy with non-vitamin K antagonist oral anticoagulant therapy during ablation could be a superior approach in the future. The trial is limited somewhat by its open label design, and also by the fact that there was only 66% adherence (measured by INR in the 2.0 to 3.0 range) in the warfarin group compared to mean adherence of 97.6% in the dabigatran group. Furthermore, while a specific dabigatran-reversal agent became available during the course of the trial, it was not utilized for the purposes of this study, and future research will necessarily incorporate this antidote into the treatment protocol. Of note, the study was funded by the producer of dabigatran.

Click to read the study, published in NEJM

RELATED REPORTS

Ablation may reduce stroke risk, death, heart failure hospitalization in patients with atrial fibrillation

The Scan by 2 Minute Medicine®: Celebrity diagnoses spur screenings, athlete mental-health push, reality-TV heart lesson, and a sitcom PSA wave

Pulsed field ablation noninferior to cryoablation for reducing paroxysmal atrial fibrillation recurrence

Relevant Reading: Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation

In-Depth [randomized controlled trial]: This randomized, open-label, multicenter, controlled trial involved 704 patients from 104 sites, 635 of whom underwent catheter ablation for paroxysmal or persistent atrial fibrillation. Patients were well matched and were randomized to receive either warfarin, titrated to achieve an INR goal of 2.0 to 3.0, or dabigatran at a dose of 150 mg twice daily, for a pre-ablation phase of 4 to 8 weeks, after which they underwent catheter ablation. The primary end point was the incidence of adjudicated major bleeding events, such as pericardial tamponade or effusion, intracranial hemorrhage, or retroperitoneal bleeding during the 8 weeks following the procedure. This occurred in significantly fewer patients in the dabigatran group compared to the warfarin group (5 patients, 1.6% vs. 22 patients, 6.9%; absolute risk difference of -5.3 percentage points 95%CI -8.4 to -2.2; p < 0.001), amounting to a relative risk reduction in favor of dabigatran of 77.2. This corresponded to an early and persistent separation of curves in the Kaplan-Meier plot over the course of follow-up. There were no strokes, embolic phenomena, or TIAs in the dabigatran group, compared to one in the warfarin group from the time of the ablation to the 8 week mark. There were similar rates of minor bleeding events in the two groups. Severe adverse events, defined as untoward medical occurrences in patients receiving a trial drug and which was incapacitating or caused an inability to work, occurred in 3.3% and 6.2% of the dabigatran and warfarin groups, respectively.

Image: PD

©2017 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: atrial fibrillationdabigatranwarfarin
Previous Post

Price transparency in electronic health records not linked to changes in physician ordering: The PRICE trial

Next Post

Recent trends in infant and toddler food and beverage consumption

RelatedReports

Atrial fibrillation-specific management increases days alive and out of hospital
Cardiology

Ablation may reduce stroke risk, death, heart failure hospitalization in patients with atrial fibrillation

July 4, 2025
The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: Celebrity diagnoses spur screenings, athlete mental-health push, reality-TV heart lesson, and a sitcom PSA wave

July 2, 2025
Radiation dose associated with increased heart disease in Hodgkin lymphoma survivors
Cardiology

Pulsed field ablation noninferior to cryoablation for reducing paroxysmal atrial fibrillation recurrence

May 30, 2025
Rivaroxaban likely reduces risk of recurrent stroke in specific subgroup of patients with embolic stroke of undetermined source
Cardiology

Left atrial appendage closure is noninferior to oral anticoagulation after ablation for atrial fibrillation

May 21, 2025
Next Post
Recent trends in infant and toddler food and beverage consumption

Recent trends in infant and toddler food and beverage consumption

Elective colectomy associated with improved survival in ulcerative colitis

2 Minute Medicine Rewind May 1, 2017

AAP supports mindfulness of children’s media consumption

Mass shootings associated with large increases in handgun acquisitions in the following 6 weeks

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Oral vancomycin may be effective for pouchitis in inflammatory bowel disease
  • Inebilizumab improves outcome in patients generalized myasthenia gravis
  • Medbridge turns any phone into a motion-capture coach for at-home rehab
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.